Comparison of edoxaban and enoxaparin in a rat model of AlCl3-induced thrombosis of the superior sagittal sinus
Authors:
- M. HachenbergerMHM. Hachenberger
- M. YeniguenMYM. Yeniguen
- L. SuennerLSL. Suenner
- D. HinchliffeDHD. Hinchliffe
- C. MuellerCMC. Mueller
- A. WietelmannAWA. Wietelmann
- T. GerrietsTGT. Gerriets
- M. TschernatschMTM. Tschernatsch
- M. JuenemannMJM. Juenemann
- S. T. GernerSGS. T. Gerner
- T. R. DoeppnerTDT. R. Doeppner
- H. B. HuttnerHHH. B. Huttner
Open Access
- 1 June 2023
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 396 (12) , 3887-3892
Abstract
Cerebral sinus venous thrombosis (CSVT) is an uncommon disease that is usually treated with anticoagulation (heparin, low-molecular heparin, or vitamin K-antagonists). We compared treatment with edoxaban, an oral factor Xa-antagonist, that has not been approved in patients with CSVT, with enoxaparin, a well-established therapy, in a rat model of CSVT. Fifty male Wistar rats were randomized into 5 groups (10 animals each) and subjected to aluminum chloride (AlCl3)-induced thrombosis of the superior sagittal sinus (SSS) or sham procedure. Animals with thrombosis of the SSS were treated with edoxaban, enoxaparin, or placebo. Diagnostic workup included neurological examination, MRI imaging, MR-flow measurements of the SSS, and immunohistochemical staining. Neurological examination revealed no differences between treatment groups. Seven days after initial thrombosis, flow in the SSS was lower in the active treatment group as compared to sham-operated animals (p < 0.05). Flow in the SSS in the active treatment groups (edoxaban 1 h prior to thrombosis: 0.16 cm/s ± 0.06 cm/s; edoxaban 6 h after thrombosis: 0.13 cm/s ± 0.05 cm/s; enoxaparin: 0.13 cm/s ± 0.04 cm/s; placebo: 0.07 cm/s ± 0.02 cm/s) was higher as compared to placebo (p < 0.05), but there were no differences between the active treatment groups (p > 0.05). Immunohistochemical staining showed no differences in the actively treated animals. Edoxaban proved to be similar to enoxaparin in a model of experimental AlCl3-induced CSVT.Keywords
Funding Information
- Daiichi Sankyo Company
- Justus-Liebig-Universität Gießen
This publication has 14 references indexed in Scilit:
- Edoxaban improves venous thrombosis via increasing hydrogen sulfide and homocysteine in rat modelMolecular Medicine Reports, 2017
- Risk impact of edoxaban in the management of stroke and venous thromboembolismVascular Health and Risk Management, 2016
- Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinuxThrombosis Research, 2016
- PI3K/Akt in platelet integrin signaling and implications in thrombosisAdvances in Biological Regulation, 2015
- Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in ratsThrombosis Research, 2012
- Angioarchitectural changes in subacute cerebral venous thrombosis. A synchrotron-based micro- and nano-CT studyNeuroImage, 2010
- DU‐176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profilesJournal of Thrombosis and Haemostasis, 2008
- Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort studyThe Lancet Neurology, 2007
- Cerebral embolic ischemia in rats: Correlation of stroke severity and functional deficit as important outcome parameterBrain Research, 2007
- The Rotarod Test: An Evaluation of Its Effectiveness in Assessing Motor Deficits Following Traumatic Brain InjuryJournal of Neurotrauma, 1994